Loading
Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma.
Constantine Tam (Alfred Health, Melbourne) was principal investigator of SEQUOIA, which established zanubrutinib over bendamustine-rituximab in untreated CLL, and led the AIM study, the first trial to combine ibrutinib and venetoclax in mantle cell lymphoma, which produced unexpectedly high complete remission rates. He led the first-in-human zanubrutinib trial and leads lymphoma at Alfred Health.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tags cll, australia.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia and the tag cll.